Literature DB >> 1445023

The prevalence of asthma in Victorian adults.

M Abramson1, J Kutin, G Bowes.   

Abstract

To determine the prevalence of asthma in Victorian adults, we carried out a cross-sectional postal survey utilising a new screening questionnaire which gathered data on self reported respiratory symptoms, whether asthma had been diagnosed and, if so, how it had been treated. Questionnaires were returned by 2198 (72%) of 3095 adults selected randomly from the Victorian electoral roll, an adequate response rate. The reported prevalences of individual asthmatic symptoms in the last 12 months ranged from 8% for nocturnal wheeze to 22% for current wheeze. Thirteen per cent of respondents had ever had asthma, 7% had experienced an attack within the last 12 months and 6% were currently taking medication. The high prevalence of asthma revealed by our study has major implications for the planning of health services.

Entities:  

Mesh:

Year:  1992        PMID: 1445023     DOI: 10.1111/j.1445-5994.1992.tb02148.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  5 in total

1.  Prevalence of asthma in adults in Busselton, Western Australia.

Authors:  J K Peat; M Haby; J Spijker; G Berry; A J Woolcock
Journal:  BMJ       Date:  1992-11-28

2.  Evaluation of a randomised controlled trial of adult asthma education in a hospital setting.

Authors:  O Abdulwadud; M Abramson; A Forbes; A James; E H Walters
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

Review 3.  Changing approaches to asthma management in Australia: effects on asthma morbidity.

Authors:  E Comino; R Henry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Asthma, allergy, and atopy in three south-east Asian populations.

Authors:  R Leung; P Ho
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

5.  Prevalence of asthma and risk factors among Chinese, Malay, and Indian adults in Singapore.

Authors:  T P Ng; K P Hui; W C Tan
Journal:  Thorax       Date:  1994-04       Impact factor: 9.139

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.